MNKD Jan 2025 3.000 call
| Previous close | 2.7100 |
| Open | 2.4000 |
| Bid | 2.1500 |
| Ask | 2.6000 |
| Strike | 3.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.4000 - 2.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.43k |
GlobeNewswireINHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual careMore than 50% of subjects at the end
Simply Wall St.Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...
GlobeNewswireInhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumpsINHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for pat
